Qualigen Therapeutics Stock In The News

QLGN Stock  USD 4.83  0.41  9.28%   
Our overall analysis of Qualigen Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Qualigen Therapeutics. The specific impact of Qualigen Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Qualigen Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Qualigen Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Qualigen Therapeutics Backtesting and Qualigen Therapeutics Hype Analysis.
To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.

Qualigen Therapeutics Today Top News and Investor Outlook

Yahoo News
Lifecore Biomedical Announces Cooperation Agreement with 22NW
https://finance.yahoo.com/news/lifecore-biomedical-announces-cooperation-agreement-120000119.html
 Neutral
Macroaxis News: globenewswire.com
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
https://www.globenewswire.com/news-release/2023/11/14/2780571/0/en/Qualigen-Therapeutics-Provides-Corporate-Update-for-Third-Quarter-and-To-Date-2023.html
 Neutral
Macroaxis News: globenewswire.com
Qualigen Therapeutics Announces First Pa...
https://www.globenewswire.com/news-release/2023/11/07/2775116/0/en/Qualigen-Therapeutics-Announces-First-Patient-Dosed-in-the-Phase-1a-Clinical-Trial-of-QN-302-for-Treatment-of-Advanced-or-Metastatic-Solid-Tumors.html
 Neutral
Macroaxis News: globenewswire.com
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer
https://www.globenewswire.com/news-release/2023/10/23/2764724/0/en/Poster-Highlighting-Qualigen-Therapeutics-Pan-RAS-Inhibitor-Platform-Presented-at-AACR-Special-Conference-Advances-in-Breast-Cancer.html
 Neutral
Macroaxis News: globenewswire.com
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023
https://www.globenewswire.com/news-release/2023/09/27/2750380/0/en/Qualigen-Therapeutics-Presents-Scientific-Data-on-QN-302-at-AACR-Special-Conference-Pancreatic-Cancer-2023.html
 Neutral
Macroaxis News: globenewswire.com
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors
https://www.globenewswire.com/news-release/2023/08/17/2727243/0/en/Qualigen-Therapeutics-Partners-with-TD2-for-Phase-1-Clinical-Development-of-QN-302-for-the-Treatment-of-Advanced-or-Metastatic-Solid-Tumors.html
 Neutral
Macroaxis News: globenewswire.com
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
https://www.globenewswire.com/news-release/2023/08/15/2725473/0/en/Qualigen-Therapeutics-Inc-Reports-Financial-Results-and-Corporate-Update-for-Quarter-Ending-June-30-2023.html
 Neutral
Macroaxis News: globenewswire.com
Qualigen Therapeutics Announces US FDA I...
https://www.globenewswire.com/news-release/2023/08/01/2715847/0/en/Qualigen-Therapeutics-Announces-US-FDA-IND-Clearance-to-Initiate-Phase-1-Clinical-Trial-of-QN-302-for-Treatment-of-Advanced-or-Metastatic-Solid-Tumors.html
 Neutral
Macroaxis News: globenewswire.com
Qualigen Therapeutics Divests FastPack® Diagnostics Business
https://www.globenewswire.com/news-release/2023/07/24/2709498/0/en/Qualigen-Therapeutics-Divests-FastPack-Diagnostics-Business.html
 Neutral
Macroaxis News: globenewswire.com
Poster Highlighting Qualigen Therapeutic...
https://www.globenewswire.com/news-release/2023/06/05/2681940/0/en/Poster-Highlighting-Qualigen-Therapeutics-Pan-RAS-Inhibitor-Platform-Presented-at-American-Society-of-Clinical-Oncology-ASCO-2023-Annual-Meeting.html
 Neutral

Qualigen Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Qualigen and other traded companies coverage with news coverage. We help investors stay connected with Qualigen headlines for the 23rd of November to make an informed investment decision based on correlating the impacts of news items on Qualigen Stock performance. Please note that trading solely based on the Qualigen Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Qualigen Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Qualigen Therapeutics investors visualize upcoming and past events in order to time the market based on Qualigen Therapeutics noise-free hype analysis.
Qualigen Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Qualigen earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Qualigen Therapeutics that are available to investors today. That information is available publicly through Qualigen media outlets and privately through word of mouth or via Qualigen internal channels. However, regardless of the origin, that massive amount of Qualigen data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Qualigen Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Qualigen Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Qualigen Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Qualigen Therapeutics alpha.

Qualigen Largest EPS Surprises

Earnings surprises can significantly impact Qualigen Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-08-14
2023-06-30-0.52-0.68-0.1630 
2023-05-15
2023-03-31-1.3-1.00.323 
2022-11-14
2022-09-30-1.3-1.00.323 
2022-04-01
2022-03-31-1.7-2.0-0.317 
2021-12-31
2021-12-31-1.7-2.0-0.317 
2021-05-14
2021-03-31-1.6-1.30.318 
View All Earnings Estimates

Qualigen Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Qualigen Therapeutics Stock. Current markets are strongly bullish. About 89% of major world exchanges and indexes are currently up. See today's market update for more information.
Gurufocus Stories at Macroaxis
19th of November 2024
Qualigen Therapeutics Announces 4.5 Million Private Placement of Convertible Preferred Sha...
at gurufocus.com 
Macroaxis News
7th of November 2024
Insider Trading
at MacroaxisInsider 
Macroaxis News
18th of October 2024
Acquisition by Shishir Sinha of 100000 shares of Qualigen Therapeutics subject to Rule 16b...
at MacroaxisInsider 
Yahoo News
26th of September 2024
Qualigen Therapeutics, Inc. Announces management changes.
at finance.yahoo.com 
news
9th of September 2024
Qualigen Therapeutics Raises 3.47 Million Through Public Offering, Plans Accelerated Debt ...
at kalkinemedia.com 
seekingalpha News
5th of September 2024
Qualigen Therapeutics stock falls after it prices 3.46M public offering
at seekingalpha.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Qualigen Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Qualigen Therapeutics' short interest history, or implied volatility extrapolated from Qualigen Therapeutics options trading.
When determining whether Qualigen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Qualigen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Qualigen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Qualigen Therapeutics Stock:
Check out Qualigen Therapeutics Backtesting and Qualigen Therapeutics Hype Analysis.
To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qualigen Therapeutics. If investors know Qualigen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qualigen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
3.6 K
Revenue Per Share
1.034
Quarterly Revenue Growth
0.137
Return On Assets
(0.75)
Return On Equity
(8.42)
The market value of Qualigen Therapeutics is measured differently than its book value, which is the value of Qualigen that is recorded on the company's balance sheet. Investors also form their own opinion of Qualigen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Qualigen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qualigen Therapeutics' market value can be influenced by many factors that don't directly affect Qualigen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Qualigen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Qualigen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qualigen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.